Back to Search Results
Image Place holder

Hammad Tashkandi, MD

 
Specialty: Pathology
Program: Pathology

Call 1-888-663-3488

Call 1-888-663-3488


Locations:
Overview

Dr. Tashkandi obtained his MD from Taibah University College of Medicine, Medina, Saudi Arabia. He completed a Research Fellowship in the Department of Pathology at the George Washington University School of Medicine and Health Sciences and a Pathology Residency at the University of Texas Health Science Center at San Antonio, where he also served as Chief resident. He then completed a Hematopathology Fellowship at Memorial Sloan Kettering Cancer Center. He recently completed a Molecular Genetics Pathology Fellowship at University of Pittsburgh Medical Center. Dr. Tashkandi’s clinical focus is to diagnose, prognosticate, and monitor hematologic malignancies, and to guide patient-specific therapy. His research interests include studying the morphologic, immunophenotypic, and genetic changes of hematologic malignancies and their impact on patients. He is also interested in minimal residual disease detection and molecular hematopathology education.


Education & Training

Participating Trials

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.

Publications

  • Zhang L, Shah B, Zhang Y, Tashkandi H, Xiao W, Fernandez-Pol S, Vergara-Lluri M, Hussaini M, Song J, Lancet J, Moscinski L, Yun S, Lu CM, Medeiros LJ, Tang G. Clinicopathologic characteristics, genetic features, and treatment options for acute lymphoblastic leukemia with JAK2 rearrangement-A 10-case study and literature review. Hum Pathol. 2023 Mar. Pubmedid: 36958463.
  • Hennawi M, Pakasticali N, Tashkandi H, Hussaini M. Genomic Landscape of Mixed-Phenotype Acute Leukemia. Int J Mol Sci. 2022 Sep.23(19). Pubmedid: 36232559. Pmcid: PMC9569865.
  • Albakri MM, Huang SC, Tashkandi HN, Sieg SF. Fatty acids secreted from head and neck cancer induce M2-like Macrophages. J Leukoc Biol. 2022 Oct.112(4):617-628. Pubmedid: 35213745.
  • Tashkandi H, Verdoni A, West M, Yatsenko S, Swerdlow SH, Aggarwal N. Enhancing Molecular and Cytogenetic Fellow Education With an Integrative Hematopathology/Molecular Genetic Pathology Joint Conference. Am J Clin Pathol. 2022 Jul.158(1):112-121. Pubmedid: 35142790.
  • Albakri M, Tashkandi H, Zhou L. A Review of Advances in Hematopoietic Stem Cell Mobilization and the Potential Role of Notch2 Blockade. Cell Transplant. 2020 Jan.29. Pubmedid: 32749152. Pmcid: PMC7563033.
  • Tashkandi H, Dogan A. Histiocytic sarcoma arising in patient with history of clonally-related germ cell tumour and myelodysplastic syndrome. Brit J Haematol. 2020 Feb.188(4):482. Pubmedid: 31978941.
  • Tashkandi H, Petrova-Drus K, Batlevi CL, Arcila ME, Roshal M, Sen F, Yao J, Baik J, Bilger A, Singh J, de Frank S, Kumar A, Aryeequaye R, Zhang Y, Dogan A, Xiao W. Divergent clonal evolution of a common precursor to mantle cell lymphoma and classic Hodgkin lymphoma. Cold Spring Harb Mol Case Stud. 2019 Dec.5(6). Pubmedid: 31395597. Pmcid: PMC6913152.
  • Tashkandi H, Cohen ML, Couce ME. Secondary diffuse large B cell lymphoma of the central nervous system: retrospective review of case series. Ann Hematol. 2019 Apr.98(4):1049-1050. Pubmedid: 30182348.
  • Tashkandi H, Shameli A, Harding CV, Maitta RW. Ultrastructural changes in peripheral blood leukocytes in α-synuclein knockout mice. Blood Cells Mol Dis. 2018 Nov.73:33-37. Pubmedid: 30195626. Pmcid: PMC6163077.
  • Tashkandi H, Moore EM, Tomlinson B, Goebel T, Sadri N. Co-occurrence of type I CALR and two MPL mutations in patient with primary myelofibrosis. Ann Hematol. 2017 Aug.96(8):1417-1418. Pubmedid: 28502030.

Patient Comments
Overall Satisfaction
0
★★★★★
★★★★★

0 patients rated this provider

The Provider Rating is an average of all responses to specific care provider-related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. These surveys assess the experience of our patients when visiting us for an Outpatient Clinic, Urgent Care or Virtual Health (Telemedicine) visit. Responses are measured on a scale of 1 to 5 with 5 being the best score.

Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

Learn more about our patient satisfaction survey

Comments ()

Comments are gathered from specific care provider-related questions from our Patient Satisfaction Survey . The comments are submitted by patients and reflect their views and opinions. Patients are de-identified for confidentiality and patient privacy.

We post both positive and negative comments from the surveys. We do not post comments that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may risk the privacy of our patients. A “[…]” in the comments below indicates de-identified patient information or comments that are unrelated to the patient’s experience with the visit to the provider, such as comments related to another provider, about the survey itself, or otherwise completely off-topic.

Not all providers will have a star rating or comments. In order to ensure accuracy of our ratings, we only display ratings for providers who have a minimum of 30 completed from the previous 12 months.

Learn more about our patient comments

Provider Ratings and comments are gathered from our nationally-recognized Press Ganey Patient Satisfaction Survey. If a provider does not have ratings or comments listed it can be for several reasons, including:

  • The provider has not yet received the minimum number of patient satisfaction surveys to be eligible for display. We require a minimum of 30 surveys before we post results to ensure that the rating is statistically reliable and a true reflection of patient satisfaction.
  • He or she may be a researcher or other type of provider that does not see patients.
  • The provider practices in a specialty or office that does not use the specified surveys currently used for these ratings.
Learn more about our patient satisfaction survey, ratings and comments